Skip to content

Welcome to Discover Pharma! Today is : November 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

idiopathic pulmonary fibrosis

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Nuformix agrees heads of terms to acquire Biovara

    Nuformix has signed heads of terms to acquire Biovara, adding [...]

    November 12, 2026
  • Advanced Therapies,Clinical & Regulatory,Digital & Data,Research & Development,Therapeutic Areas

    Brainomix to present five ILD studies on quantitative CT at ERS Congress

    Brainomix will present five studies examining quantitative CT biomarkers in [...]

    August 25, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Jascayd approval expands treatment options for pulmonary fibrosis in Europe

    Boehringer Ingelheim’s Jascayd has received European marketing authorisation for idiopathic [...]

    August 4, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Cereno Scientific broadens CS014 development focus to pulmonary hypertension linked to interstitial lung disease

    Cereno Scientific has broadened the clinical development focus of its [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data

    Qureight AI imaging to power Calluna’s Phase 2 IPF trial

    Qureight, a techbio company advancing the understanding of lung and [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Cereno Scientific’s CS014 shows encouraging phase 1 results in idiopathic pulmonary fibrosis

    Cereno Scientific, a biotechnology company pioneering treatments for rare cardiovascular [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    AI validation of rentosertib efficacy supports global trial expansion in IPF

    Qureight’s deep-learning biomarkers confirm representativeness of Insilico’s Phase 2a IPF [...]

    May 5, 2026
  • Clinical & Regulatory

    Rein Therapeutics to integrate Qureight’s Deep-Learning Imaging Platform in Upcoming IPF Trial

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neurizon advances NUZ-001 ALS trial into treatment extension
    Categories: Clinical & Regulatory
  • ViiV HIV medicines receive positive EU opinion for younger children
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Ofichem agrees to acquire US CDMO Kinentia Biosciences
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top